Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Optimizing the Experience of Patients with Bladder Cancer Through Multi-Disciplinary Care

Pfizer

Bladder cancer is the 10th leading cause of cancer death in the United States. According to the American Cancer Society, over 84,000 new patients will be diagnosed with bladder cancer in 2025, and over 17,000 patients will succumb to the disease. The bladder cancer therapeutic landscape is rapidly evolving, with advancements in both detection and available treatment options. With this rapid change comes significant variations in the quality of care and outcomes for patients with bladder cancer.

Bladder cancer is a heterogeneous condition, spanning early disease (e.g. non-muscle invasive bladder cancer [NMIBC]) through advanced/metastatic disease. As such, the delivery of optimal bladder cancer care across the disease continuum requires multi-disciplinary teams including urologists, medical, surgical, and radiation oncologists, key advanced practice providers and patient navigators. Patients with bladder cancer are treated in diverse practice settings and their experiences can be uniquely complex and stressful. As clinicians and patients embrace advances in the therapeutic landscape, the goal of this competitive grant program is to support quality improvement projects that aim to address known gaps in the multi-disciplinary care of patients with bladder cancer throughout the care continuum (NMIBC, muscle-invasive bladder cancer [MIBC] and metastatic urothelial carcinoma [mUC]).

There are a number of gaps that impact the experiences and outcomes of patients with bladder cancer, which may be addressed through quality improvement approaches. These include, but are not limited to:

• Addressing timely treatment initiation.

• Selecting the optimal treatment for each patient, including appropriate timing and followup care.

• Clear communication to patients regarding treatment options and what to expect during treatment, in particular identification of adverse events.

• Shared decision making across the care team, including (but not limited to) nurses, urologists, and medical, surgical, and radiation oncologists.

• Uniform application of care guidelines across different practice settings.

• Patient access to counseling pertaining to their care to provide knowledge that empowers them to make informed decisions. This grant awards program was purposefully developed in collaboration between Pfizer, Conquer Cancer, the ASCO Foundation, The American Society for Radiation Oncology (ASTRO), and Large Urology Group Practice Association (LUGPA). The scientific focus of the program is guided by bladder cancer experts representing patients, urologists, medical, surgical, and radiation oncologists and expressly to meet the needs of patients with bladder cancer.

Project Budget and Duration This opportunity is intended to support quality improvement projects with an 18-24 month duration, and a maximum budget of $250,000.

Specialties

Oncology

Eligibility Requirements

• Community clinics treating patients with bladder cancer are highly encouraged to apply.

• The following institutions may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); independent practice groups; professional organizations; government agencies; and other entities with a mission related to healthcare improvement.

• Only organizations and independent practice groups are eligible to receive grants, not individual professionals or solo practices.

• The primary applicant must be US based. However, collaborative sites outside the US are permissible.

• Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions / organizations / associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.

• The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI’s grant/research coordinator).

• The Project Lead/PI must be an employee or contractor of the requesting organization.

• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

• For projects offering continuing education credit, the requesting organization must be accredited.

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: Pfizer

Sponsor Type: Corporate/Non-Profit

Address: 66 Hudson Boulevard East New York, NY 10001-2192

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity